Glutoxim injection 2ml amp 3% 5 pcs

Description

Composition
Active substance:
Glutamyl-cysteinyl-glycine disodium 5 mg, 10 mg or 30 mg in 1 ml.
Excipients:
Sodium acetate, diluted acetic acid, water for injection.
Description:
Transparent colorless or weakly colored liquid odorless or low-odor of acetic acid.
Product form:
Injection 5, 10, 30 mg / ml.
1 or 2 ml ampoules made of neutral glass.
5 or 10 vials (containing 1 ml or 2 ml) in blisters of PVC film and aluminum foil or varnished printed paper with a single layer coating polyvinylidene chloride.
5 or 10 vials (containing 1 ml or 2 ml) in blisters of PVC film without a foil or coating.
1, 2, 5 or 10 (containing 5 or 10 vials) packages contour with a knife or lancet ampoule together with instructions for use in a pile of cardboard.
When packing ampoules grooved rings and scarifiers fracture points or knives do not invest ampoule.
Contraindications
Use of the drug is contraindicated in cases of individual intolerance, pregnancy, lactation.
Dosage
3%
Indications
Glutoxim® used in adults as a means of prevention and treatment of secondary immunodeficiency conditions associated with radiation, chemical and infectious factors for restoration of depressed immune response and hematopoiesis of depression of bone marrow; to increase resistance to a variety of pathological influences – infectious agents, chemical and / or physical factors (toxicity, radiation, etc.); as a hepatoprotective agent for chronic viral hepatitis B and C; to potentiate the therapeutic effects of antibiotic therapy for chronic obstructive pulmonary diseases; for the prevention of postoperative septic complications. Injection of 10 and 30 mg / ml are used in the complex antituberculous therapy of severe forms of tuberculosis common in all locations, the presence of drug resistance of Mycobacterium tuberculosis, to prevent relapse of chronic hepatitis C in patients with tuberculosis in TB treatment, for treating toxic complications antituberculous therapy. A solution for injection is used in the complex therapy of psoriasis, including moderate and severe forms of the presence erythroderma, arthropathy.
Glutoxim® used in the treatment of malignancies. Glutoxim® used in oncology for the prevention and treatment of toxic effects of chemotherapy and radiation therapy (hemo reduces and hepatotoxicity). Glutoxim® promote the effective restoration of functions of bone marrow blood during anticancer therapy. Glutoxim® eliminates or smoothes manifestations nonspecific syndrome disease (anemia, fatigue, reduced appetite, increased pain sensitivity).
Interaction with other drugs
Glutoxim®, the combined use, potentiates the bacteriostatic effect of isoniazid, rifampicin, rifabutin, cycloserine, capreomycin, levofloxacin at Micobacterium tuberculosis, the anthracycline antibiotic doxorubicin, alkylating agents – etoposide on tumor cells.
Glutoxim® reduces the therapeutic effect of nifedipine and verapamil.
Inhibitors of the cyclooxygenase path oxidation of arachidonic acid – indomethacin, meloxicam reduce or completely inhibit Glutoxim® pharmacological action of the drug.
Overdose
No cases of overdose have been reported.
pharmachologic effect
Pharmacological group:
Immunostimulatory agent.
Pharmacodynamics:
Glutoxim® has immunomodulatory, hemostimulating, toksikomodifitsiruyuschee, hepatoprotective effect, suppresses the drug resistance of tumor cells to antibiotics anthracyclines, alkylating agents; overcomes drug resistance to isoniazid Micobacterium tuberculosis associated with genes katG (catalase-peroxidase gene) and inhA (gene enol-ACP reductase). Glutoxim® potentiates the effect of Doxorubicin on tumor cells, chemotherapy agents (isoniazid, rifampicin, rifabutin, cycloserine, capreomycin, levofloxacin, cationic peptide antimikrobonogo kataletsidina) on Micobacterium tuberculosis.
Immunomodulatory effects Glutoxim® drug due to receptor-mediated effect on calcium-dependent signaling pathways of macrophages, which leads to an increase in: -vyzhivaemosti and functional capacity of tissue macrophages; – submembrane exocytosis of granules with intracellular parasitic forms Micobacterium tuberculosis; – the activity of lysosomal enzymes; – generation of reactive oxygen species; – absorption and destruction of microorganisms; – secretion of cytokines: interleukin 1, interleukin 6, tumor necrosis factor, interferons, erythropoietin, interleukin 2; cationic antimicrobial peptides – defensins, kataletsidinov.
Hemostimulating action Glutoxim® drug due to receptor mediated enhancement of bone marrow hematopoiesis: erythropoiesis processes lymphopoiesis and granulocyte-monocytopoiesis. Effect on progenitor cells of different lines of blood cells is mediated by the functioning of the MAP- and inositol kinase systems, leads to increased stability of the differentiated hematopoietic cells, restores their sensitivity to the action of endogenous factors hematopoiesis.
Toksikomodifitsiruyuschy and hepatoprotective effects of the drug caused by receptor mediated enhancement of expression of enzymes second phase detoxification of xenobiotics, including glutathione, glutathione peroxidase, glutathione-S-transferase, glucose-6-phosphate dehydrogenase, heme oxygenase-1, increase the intracellular level of glutathione, providing protection of cellular structures against the toxic action of radicals.
Glutoxim® exerts a direct inhibitory effect on the activity of Factor multidrug resistance of tumor cells – the protein is P-glycoprotein (Rgp) which determines the resistance of tumor cells to chemotherapy agents, including anthracycline antibiotics, alkylating agents action.
Glutoxim® initiates a reaction of transformation of isoniazid – prodrug thereof, in a pharmacologically active form – isonicotinic acid, having bacteriostatic action on Micobacterium tuberculosis, which allows to overcome drug resistance Micobacterium tuberculosis, caused by the transformation of the negative gene katG (catalase-peroxidase gene) and inhA (enol-ACP gene reductase).
Glutoxim® stimulates exocytosis of vesicle macrophages intracellularly parasitic microorganism, including Micobacterium tuberculosis, enabling their removal from the pharmacological seekers and making accessible to the action of antibacterial drugs including isoniazid, rifampicin, rifabutin, cycloserine, capreomycin, levofloxacin.
Glutoxim® enhances secretion cationic peptides – defensins and kataletsidinov macrophages, stimulates their absorption Mycobacterium tuberculosis, identifying indirect antibacterial effect of the preparation.
Pharmacokinetics:
Glutoxim® refers to a group of natural metabolites that determines the characteristics of its metabolism by existing cellular enzymatic systems. After intramuscular, intravenous or subcutaneous injection, the bioavailability is greater than 90%. Observed a linear relationship between dose and concentration of drug in the blood plasma. The maximum drug concentration in plasma when administered intravenously observed within 2-5 minutes after intramuscular -. For 7 – 10 min. As a natural product peptide, Glutoxim® metabolized in organs and tissues of the body with elimination through the kidneys.
Conditions of supply of pharmacies
On prescription.
side effects
In some patients there may be a slight increase in temperature (up to 37,10 C – 37.50 C), soreness at the injection site of the drug. With poor tolerability subjective pain Glutoxim® administered together with 1 – 2 ml 0.5% novocaine solution.
special instructions
The carrier solution for infusion administration, an isotonic sodium chloride solution or 5% glucose solution.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Glutoxim® drug is administered intravenously, intramuscularly, subcutaneously. Administer daily 5 – 40 mg (at a rate of 1 – 50 – 300 mg) depending on the nature of the disease.
With prophylactic drug is used intramuscularly 5-10 mg daily for 2 weeks.
In the complex treatment of tuberculosis Glutoxim® 60 mg administered first 10 days of 1 times a day every day intramuscularly next 20 days Glutoxim® 60 mg intramuscularly every other day, one injection per day.
If necessary, a second course of treatment after 1-6 months.
In the combined therapy of psoriasis Glutoxim® applied intramuscularly daily dose of 10 mg for 15 days, then for additional 2 weeks, 5 times a week in a daily dose of 10 mg. Only 25 injections per course of treatment.
As a means of support in oncology chemotherapy Glutoxim® 60 mg subcutaneously injected 1.5-2 hours prior to application of antitumor agents. Further, between courses of chemotherapy Glutoxim® 60 mg administered subcutaneously every other day. When the next course of chemotherapy drug application circuit repeats.
As a means of tracking radiation therapy Glutoxim® 60 mg administered subcutaneously every 0.5-1 hour after the next session of irradiation in a day throughout the course of radiotherapy.
Glutoxim® may be administered in the same syringe with water soluble medicaments.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist